Egyt Gyogyszervegyeszeti Gyar

Egis Gyogyszergyar

Egis Gyogyszergyar Rt.

Denes Bezzegh

Pal Fekete

Attila Mandi

Zoltan Toth

Janos Egri

Karoly Magyar

Imre Klebovich

Jozsef Kelemen

Erzsebet Barczay

Katalin Zukovics Nee Sumeg

Sandor Drabant

Gyorgy Ujfalussy

Sandor Erdos

Erzsebet Fellner, Nee Kohalmi

Magdolna Gora, Nee Hernyes

Andrea Sandorfalvy

Olga Magyar

Marta Szanto

Biborka Maroshelyi, Nee Kovacs

Katalin Sumeg

Zsuzsa Szlavy, Nee Szell

Gabor Zalai

Janos Tombor

Ilona Bor

Erzsebet Fellner

Zsuzsanna Jambor neHoffmann

Tibor Kovacs

Eva Tamas

Katalin Zukovics neSte,uml/u/ Megh

Ilona Bor Nee Baumgartner

The invention relates to oral solid pharmaceutical composition containing as active ingredient gemfibrozil and conventional pharmaceutical auxiliary agents comprising as surfactant bis-(2-ethyl-hexyl)-sodium-sulfosuccinate in an amount of 0.05-0.5% by weight relative to gemfibrozil content of the composition. The pharmaceutical compositions according to the present invention contain a relatively small amount of a surfactant, provide uniform dissolution of the active ingredient among the different batches and the standard deviation of the dissolution rate is low.

Gemfibrozil containing pharmaceutical compositions

The invention relates to a process for the preparation of solid pharmaceutical compositions. More specifically, the invention relates to a process for the preparation of tablets ensuring an increased active ingredient release, where said tablets comprise as active ingredient a mixture of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid in a (3-12):1 mass to mass ratio, which comprises admixing any of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid, or both of them, with a hydrophilic diluent, preferably lactose and/or microcrystalline cellulose, and optionally with a colouring agent, blending the mixture thus obtained with auxiliary agents conventionally used for the preparation of tablets and optionally with the other active ingredient, furthermore with a solution of stearin in an appropriate solvent, preferably an alkanol comprising 2 to 4 carbon atoms, drying and granulating the mixture thus obtained, optionally admixing further auxiliary agent(s) to the dry granulate, compressing it into tablets comprising 50 to 70% by mass of active ingredient and, if desired, applying a film-coating onto the surface of the tablets thus obtained. The process according to the invention provides tablets of appropriate quality with rapid active ingredient release.

Process for the preparation of solid pharmaceutical compositions

The invention relates to the preparation of microcapsules ensuring direct tablet compression of a drug and rapid release of the drug as active ingredient from the tablets, which comprises microencapsulating the crystal granules of cyclohexane-insoluble active ingredients with a particle size of at most 1000 .mu.m, preferably smaller than 60 .mu.m and particularly preferably smaller than 30 .mu.m, in cyclohexane medium with ethylcellulose taken in an amount of 1:30 to 1:5, preferably 1:20 to 1:10, in relation to the core material, if desired, in the presence of 0.001 to 1.0% by weight/volume, preferably 0.01 to 0.05% by weight/volume, of an anionic surface-active agent; or post-treating the drug granules microencapsulated with ethylcellulose by a cyclohexane-dissolved surface-active agent taken in an amount of 0.001 to 1.0% by weight/volume, preferably 0.1 to 0.5% by weight/volume, in relation to cyclohexane.

Process for preparing microcapsules providing the rapid release of a

Process for the preparation of sustained release pharmaceutical

The invention refers to a powder mixture having a high propylene glycol content and a process for the preparation thereof. The powder mixture consists of 25 to 75 percent by weight of propylene glycol and 75 to 25 percent by weight of magnesium oxide and/or magnesium peroxide and/or magnesium carbonate as a solid carrier(s). The powder mixture can be treated as a solid powder and it does not deliquesce in the air even when stored for a long time. The mixture can be used as solid propylene glycol in dietetic products for calf, piglet and lamb, in pharmaceutical compositions for the treatment of ketosis and in other pharmaceutical compositions for veterinary use.

Powder mixture having high propylene glycol content and process for the

The invention provides a method for preparing sustained release tablets comprising a hydrophilic polymer matrix, which amounts to at least 10% by weight of the composition, consisting of a 5:1-1:5 weight to weight ratio mixture of a VP-VA copolymer and of an acrylic acid homopolymer, cross-linked with polyallyl saccharose. The method of manufacturing of sustained release tablets according to the invention can be accomplished in two ways: either by manufacturing the granulate containing the active ingredient, or by supplementing the matrix granulate containing no active ingredient with the suitable amount of the active ingredient. The latter variant involves the advantage of a possible separation of large-scale manufacturing of pharmacons and that of a generally applicable retardizing system, the composition and, consequently, the retardizing ability of which can optionally be modified in accordance with the properties of the active ingredient(s) to be formulated.

Sustained release pharmaceutical tablets and process for the preparation

Growing community of inventors

Budapest, Hungary

Denes Bezzegh